Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria

Journal of International Medical Research

Volumn 40, Issue 2, 2012, Pages 798-803

  Nakamura, T ^a   Sato, E ^a   Amaha, M ^a   Kawagoe, Y ^a   Maeda, S ^b   Inoue, H ^c   Yamagishi, S I ^b  

^a Department of Gastroenterology and Hepatology Shinmatsudo Central General Hospital   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Albuminuria; Diabetic nephropathy; Ezetimibe; Hypercholesterolaemia; monocyte chemoattractant protein 1

Indexed keywords

ALBUMIN; CREATININE; EZETIMIBE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG RESPONSE; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY ALBUMIN EXCRETION; URINARY EXCRETION;

EID: 84860493918     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000246     Document Type: Article

References (15)

1. Adler AI, Stevens RJ, Manley SE, et al: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
2. Yamagishi S, Matsui T, Nakamura K: Atorvastatin and diabetic vascular complications. Curr Pharm Des 2006; 12: 1549-1554.
3. Colhoun HM, Betteridge DJ, Durrington PN, et al. for CARDS Investigators: Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). Am J Kidney Dis 2009; 54: 810-819.
4. Nakamura T, Sugaya T, Kawagoe Y, et al: Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005; 28: 2728-2732.
5. Nakamura T, Sato E, Fujiwara N, et al: Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Pharmacol Res 2009; 60: 525-528.
6. Nakamura K, Yamagishi S, Adachi H, et al: Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 109-114.
7. Laker MF: Laboratory testing and biochemical analysis of hyperlipidaemias. Postgrad Med J 1993; 69(suppl 1): S12-S17.
8. Imai E, Horio M, Nitta K, et al: Estimation of glomerular filtration rate by MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 2007; 11: 41-50.
9. Chiarelli F, Cipollone F, Mohn A, et al: Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 2002; 25: 1829-1834.
10. Takebayashi K, Matsumoto S, Aso Y, et al: Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese type 2 diabetic patients. J Diabetes Complications 2006; 20: 98-104.
11. Fornoni A, Ijaz A, Tejada T, et al: Role of inflammation in diabetic nephropathy. Curr Diabetes Rev 2008; 4: 10-17.
12. Matsui T, Yamagishi S, Takeuchi M, et al: Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activatedreceptor-gamma activation. Biochem Biophys Res Commun 2009; 385: 269-272.
13. Ueda S, Miyake I, Takata K, et al: Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia. Int J Cardiol 2011; 146: 420-421.
14. Yagi S, Akaike M, Aihara K, et al: Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. J Atheroscler Thromb 2010; 17: 173-180.
15. Ruggenenti P, Cattaneo D, Rota S, et al: for the Ezetimibe and Simvastatin in Dyslipidemia of Diabetes (ESD) Study Group: Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial. Diabetes Care 2010; 33: 1954-1956.